Core Viewpoint - The research highlights the development of engineered human mesenchymal progenitor cells (SRC) that exhibit triple resistance to aging, stress, and malignant transformation, providing a customizable cell therapy paradigm for aging intervention in primates [3][12]. Group 1: Research Background and Mechanism - Aging is characterized by the depletion of stem cell reserves, leading to decreased tissue regeneration and homeostasis, which is a key feature of aging and age-related diseases [2]. - The study published in Cell by a collaborative research team from the Chinese Academy of Sciences and Capital Medical University focuses on the mechanisms of aging regulation and the potential of SRC to counteract aging in primates [2][3]. Group 2: Development of SRC Technology - The research team utilized synthetic biology to reprogram longevity gene pathways, successfully constructing SRC with enhanced anti-aging properties [3]. - The SRC technology has evolved through various iterations, including SRC 1.0 and SRC 2.0, which involved precise genetic modifications to enhance antioxidant defenses and integrate anti-aging functionalities [6][8]. Group 3: Efficacy and Safety of SRC - The SRC cells demonstrated significant anti-aging activity and environmental adaptability, with excellent safety profiles, effectively resisting adverse effects in a primate model [8][9]. - A 44-week intervention study using SRC in aged primates showed no adverse events, confirming the safety and immune tolerance of SRC transplantation [9][11]. Group 4: Mechanistic Insights and Outcomes - SRC cells were found to release exosomes that promote cellular rejuvenation, suppress chronic inflammation, and maintain genomic stability, contributing to the delay of systemic aging [11]. - The intervention led to improvements in cognitive function, reduction of degenerative changes in multiple tissues, and a significant reversal of biological aging markers in various organs [11][12]. Group 5: Clinical Translation and Future Prospects - The study establishes a theoretical framework for stem cell transplantation to mitigate aging, addressing long-standing controversies in the field [13]. - The research opens pathways for scalable production of universal cell interventions, providing new solutions for aging and related diseases, and sets a new standard for evaluating anti-aging effects in cell therapy products [14][16]. - Future research will focus on optimizing clinical-grade production processes and understanding the interactions between SRC and the host immune system to enhance treatment strategies [18][19].

Group 1: Report Overview - The research object is Gongtong Pharmaceutical Co., Ltd., belonging to the chemical pharmaceutical industry, and the reception time was on June 12, 2025 [16]. - The participants in the research include investors who participated in the "2025 Online Collective Reception Day for Investors of Listed Companies in Hubei Province" [19]. Group 2: Company's Market Position and Strategy - In the field of steroid drug starting materials, the company has achieved large - scale production of a full range of products such as 4 - androstenedione (4 - AD), androstadienedione (ADD), 9 - hydroxyandrostenedione (9 - OH - AD), 11 - hydroxy - AD, and dihydroxyalcohol, with its production capacity scale and product variety diversity ranking among the top in the world; in the intermediate field, it has built a vertically integrated system covering the entire steroid drug industry chain and has become an important R & D and production base for steroid drug intermediates in China; in the API field, relying on the API project of its subsidiary Huahai Gongtong, it will become the first integrated supplier in China to simultaneously layout sex hormones, progestogens, corticosteroids, and other types of steroid APIs, realizing the full - chain connection from starting materials to APIs [23]. - To face market competition, the company adheres to innovation - driven development, with its product strategy focusing on three directions: deepening the integration of biotransformation and synthetic biology technologies through technological iteration to reduce the production cost of key intermediates; optimizing the automation level of existing production lines through capacity expansion to increase the proportion of high - value - added product production capacity; and continuously exploring the market, consolidating strategic cooperation with global leading pharmaceutical companies, and expanding the layout of intermediates in emerging fields such as anti - cancer and assisted reproduction [23]. Group 3: R & D - related Information - The Hubei Gongtong Steroid Research Institute, established over three years ago, aims to break through four core technologies: targeted screening of strains, targeted modification of enzyme engineering, efficient conversion of sterols, and green synthesis processes, and form a closed - loop innovation system from basic research to industrial transformation. Its technological achievements have won many authoritative certifications such as the National Science and Technology Progress Award [24][25]. - From 2022 to 2024, the company's R & D investments were 45.15 million yuan, 38.10 million yuan, and 51.08 million yuan respectively, and the proportion of R & D investment in operating income has been increasing year by year. The company has established a special R & D center to promote the R & D of new products and processes and the upgrading and optimization of existing processes [25]. Group 4: Overseas Market and Other Business Information - In 2024, the company's overseas sales accounted for 28.54%, and the proportion has been increasing year by year. In 2025, the company will continue to adhere to the international development strategy, strengthen brand promotion overseas and increase sales channels by establishing subsidiaries overseas, and seek business cooperation through overseas resources [25]. - The vitamin D3 industrialization project has been filed and is being implemented according to the company's project plan [27]. - Regarding the company's share repurchase, the period is within 12 months from the date of the board of directors' review. The company will promote the repurchase work according to market conditions and disclose the repurchase progress as of the end of the previous month at the beginning of each month [27]. - For specific information on innovative drugs such as fluvestrant, it shall be subject to the information disclosed on the company's designated information disclosure website; for the follow - up plan of convertible bonds, it shall be subject to the company's announcements; and for the question of whether the company's losses in the first half of the year will increase year - on - year after the capitalization of the raised projects, it is necessary to refer to the semi - annual report of 2025 [25][27]

Group 1: Market Position and Strategy - The company has achieved large-scale production of steroid drug starting materials, ranking among the top globally in terms of production capacity and variety [2] - It has established a vertically integrated system covering the entire steroid drug industry chain, becoming a key R&D and production base for steroid drug intermediates in China [3] - The company focuses on three strategic directions: reducing production costs through technological iteration, optimizing existing production lines to increase high-value product capacity, and expanding market presence in emerging fields like anti-cancer and assisted reproduction [3] Group 2: R&D Investment and Achievements - R&D investments from 2022 to 2024 were 45.15 million, 38.10 million, and 51.08 million CNY, respectively, with the proportion of R&D investment to revenue increasing year by year [4] - The company has established a closed-loop innovation system from basic research to industrialization, recognized with multiple awards including the National Science and Technology Progress Award [3] Group 3: International Market Expansion - In 2024, the company's product export ratio was 28.54%, showing a year-on-year increase [3] - Plans for 2025 include strengthening brand promotion and sales channels through overseas subsidiaries and seeking commercial cooperation through international resources [3] Group 4: Stock Performance and Future Plans - The company is considering stock repurchase based on market conditions, with updates provided monthly [5] - There are ongoing projects for innovative drugs, including the industrialization of Vitamin D3, which is progressing as planned [5]

Key Insights - The report highlights the significant performance of high-volatility strategies, with a cumulative increase of over 27% year-to-date, indicating strong market recovery and strategy effectiveness [2][4] - The report emphasizes the strategic transformation of Huaxi Biological, a leading global hyaluronic acid supplier, which is expected to benefit from domestic consumption upgrades and the growing demand for life health products [7][10] - The mechanical industry shows a mixed performance, with a decline in domestic excavator sales but a positive export growth, suggesting a resilient long-term outlook supported by government initiatives [12][15][16] - The beverage sector, particularly beer companies, is exploring diversification into non-alcoholic beverages, which is seen as a crucial growth strategy for future revenue streams [18][22] Group 1: High-Volatility Strategies - The report details the performance of various strategies, with low-price enhancement, improved dual-low, and high-price high-elasticity strategies yielding returns of 1.5%, 2.7%, and 4.7% respectively during the last period [2][3] - Year-to-date performance for these strategies shows returns of 4.5%, 16.6%, and 27.3%, outperforming the benchmark [2][3] Group 2: Huaxi Biological - Huaxi Biological is positioned as a global leader in bioactive materials, focusing on synthetic biology technology and a comprehensive industry chain [7][10] - The company is expanding its product matrix to include various bioactive materials, enhancing its market presence in medical and nutritional products [8][9] Group 3: Mechanical Industry - In May, domestic excavator sales decreased by 1.48%, while exports grew by 5.4%, indicating a shift in market dynamics [12][14] - The report notes that the overall export of engineering machinery remains stable, with significant growth in exports to Africa and South America [14][16] Group 4: Beverage Sector - Domestic beer companies are actively expanding into beverage markets, with notable initiatives from brands like Yanjing and Qingdao Beer [18][19] - The report suggests that while beverage business contributions are currently low, they represent a vital growth avenue for beer companies in the long term [22]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 112.78 CNY [3][4] Core Views - The company is positioned as a leading multi-brand beauty group in the new development stage, with strong competitive advantages in its main brands [2][8] - The company has a well-established multi-brand portfolio, including seven differentiated brands covering skincare, makeup, and hair care, and is the first domestic beauty company to exceed 10 billion CNY in revenue [8] - Concerns regarding the transition to the second generation of leadership are noted, but the report emphasizes the positive long-term impact of this change on the company's development [8] - The company is actively enhancing its product innovation, R&D investment, and digital transformation, indicating a strong commitment to future growth [8] - The report highlights the potential for international expansion and acquisitions as part of the company's growth strategy, particularly in new sectors such as children's products, perfumes, and men's skincare [8] Financial Forecasts - The company is projected to achieve earnings per share of 4.56 CNY, 5.36 CNY, and 6.06 CNY for the years 2025, 2026, and 2027 respectively [3][9] - Revenue is expected to grow from 8,905 million CNY in 2023 to 15,577 million CNY in 2027, with a compound annual growth rate (CAGR) of approximately 10.7% [3][11] - Operating profit is forecasted to increase from 1,503 million CNY in 2023 to 2,923 million CNY in 2027, reflecting a strong growth trajectory [3][11] - The company's gross margin is expected to improve from 69.9% in 2023 to 73.0% in 2027, indicating enhanced operational efficiency [3][11]

Group 1: Policy Release - The report includes three domestic policies related to the bio-based industry released in May 2025, focusing on carbon reduction projects [7][18]. - Key projects include a 110,000-ton biodegradable polyester rubber demonstration project and a 1 million-ton waste oil processing sustainable aviation fuel project [8][19]. Group 2: Industry Dynamics - The report highlights two domestic bio-based chemical company updates, including a 120 million yuan investment in a lactic acid production demonstration line by Heilongjiang Guoke Bio-based New Materials [9][20]. - Wanhu Chemical has established a new company focusing on food additives, with a registered capital of 200 million yuan [10]. Group 3: Capital Events - Several financing events in the bio-based sector are reported, including a multi-million yuan investment in Senqi New Materials for bio-based high barrier film materials [11][22]. - Other notable investments include a joint investment exceeding 100 million yuan in Juyuan Bio for recombinant collagen [22]. Group 4: Scientific Research Progress - Significant breakthroughs in bio-based materials research are noted, including a study on lignin-derived carbon improving catalytic performance [12][23]. - Research on a new type of printable conductive "E-skin" with antibacterial properties has been developed, mimicking slime mold characteristics [12][23]. Group 5: Upcoming Events - The Fourth Synthetic Biology and Green Bio-manufacturing Conference will be held from August 20-22, 2025, in Jinan, Shandong, focusing on the development trends of the bio-manufacturing industry [25][26].

# SynBio团队 | 中科院苏州医工所马富强 在人工生命体精准编程的"黄金时代"，合成生物学作为融合工程学、计算机科学与分子生物学的交叉学科， 正通过"设计-构建-测试"的循环模式重塑生物制造范式。这一领域不仅被列为全球科技竞争的战略高地，更在 医药研发、碳中和、农业升级等关乎国计民生的赛道上展现出颠覆性潜力。 其核心突破点聚焦 三大支柱 ： 三大支柱技术如同精密咬合的齿轮，共同决定了细胞合成工厂的效率 。 【SynBioCon】 获 悉，近日， 苏州医工所马富强研究团队 围绕上述合成生物学三大支柱技术开展了系统工 作： 图2. 利用深度学习辅助生成新型启动子的两种方法 ： 左 图 ， 通过对现有启动子引入突变或随机生成新序列 来创建新的序列。这些新生成的序列通过启动子识别模型进行筛选，以验证其功能 ；右 图 ， 使用扩散模型 或生成对抗网络（GANs）来生成新的启动子。扩散模型通过添加高斯噪声逐步生成启动子序列。GANs 由生 成器和判别器组成，生成器负责生成假样本，而判别器用于区分真实样本和生成的假样本。通过训练过程不 断优化生成器的性能，使其能够生成更逼真的启动子序列。 工作1 ： 新型酶资源 的 ...

Group 1 - Institutional investors bought a total of 30 stocks, with net purchases in 9 stocks and net sales in 21 stocks on the day [1] - The top three stocks with the highest institutional purchases were: Limin Co., Ltd. (¥193 million), Anglikang (¥170 million over three days), and Aoyang Health (¥13.56 million) [1] - Limin Co., Ltd. saw a net purchase of ¥193 million from 5 institutions, benefiting from rising prices of key products such as Abamectin and Mancozeb, which is expected to enhance its profitability [3] Group 2 - The stock of Limin Co., Ltd. increased by 10.02% with 3 buyers and 2 sellers [2] - Anglikang's stock rose by 9.98% with 4 buyers and 2 sellers [2] - The automotive industry is experiencing a shift as major companies have committed to standardizing supplier payment terms to 60 days, which may alleviate profit pressures across the industry [3]

Core Insights - A team from Colorado State University has successfully synthesized a "gene switch" that allows for the flexible activation or deactivation of key genetic traits in mature plants, marking a significant advancement in synthetic biology [1][2] - This research provides a theoretical and technical foundation for the programmable regulation of plant gene functions, enabling tailored design of plant characteristics for various applications [2] Group 1: Research Significance - The study represents a milestone in synthetic biology, enabling the creation of a genetic "switch" that functions similarly to an electronic circuit, allowing precise control over gene expression in response to external signals [1] - Prior to this, gene regulation technologies were limited to single-celled organisms, making this achievement in complex multicellular plants particularly noteworthy [1] Group 2: Applications and Future Prospects - The "gene circuit" developed can regulate different stages of plant life cycles and has potential applications in agriculture and materials science, such as enhancing drought resistance in crops or optimizing growth cycles for better yield and nutritional value [2] - Future advancements may include the use of machine learning to further optimize the design process of gene circuits, potentially automating operations and accelerating research and development [2] - This breakthrough technology is expected to contribute to food security and open new possibilities in environmental restoration and sustainable materials development, representing a significant step towards the "programming" of plant modifications [2]

Core Insights - The Chinese beauty market is experiencing significant growth driven by ingredient-focused marketing, but there is a widening gap between consumer expectations and regulatory standards [1] - The complexity of new ingredients like bioactive peptides and plant extracts has outpaced existing national standards, leading to regulatory challenges [1][7] - Social media's promotion of high-concentration ingredients has resulted in consumer misconceptions about safety and efficacy, increasing the risk of health issues [1] Group 1: Medical Applications - Hyaluronic acid (HA) is primarily used for facial filling and shaping, addressing issues like wrinkles and volume loss, while collagen is crucial for skin firmness and elasticity [2][3] - HA provides immediate results and strong moisturizing effects, but its effects last only 6-12 months, requiring regular maintenance [4] - Collagen injections take longer to show results (1-2 weeks) but can stimulate the body's own collagen production, with effects lasting 6-18 months or longer [5] Group 2: Market Dynamics - HA dominates the aesthetic filler market due to lower production costs and widespread application, while collagen's market share is smaller but growing faster [8][9] - The production cost of collagen is 3-5 times higher than that of HA, which contributes to its higher retail price [8] - High prices for collagen may slow its market penetration, particularly in emerging markets, but some consumers view the cost as a reflection of quality [9] Group 3: Regulatory and Testing Standards - Current testing methods for HA include high-performance liquid chromatography (HPLC) and gel permeation chromatography (GPC), while collagen is tested using methods like the Kjeldahl method and BCA assay [6][7] - Regulatory focus is on purity, molecular weight distribution, and biological safety, with HA standards being more established than those for collagen [7] - The rapid development of new materials outpaces the evolution of traditional quality standards, posing challenges for regulatory compliance [7] Group 4: Future Trends - The next five years may see increased integration of HA and collagen in applications aimed at improving skin hydration and elasticity [10] - Innovations in synthetic biology could lead to breakthroughs in the use of collagen in tissue engineering and regenerative medicine [10] - As competition intensifies, prices for both HA and collagen products may decrease, driven by technological advancements and market entry of new players [11]